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Abstract
The liver performs critical physiological functions, including metabolizing and removing 
substances, such as toxins and drugs, from the bloodstream. Hepatotoxicity itself is intimately 
linked to abnormal hepatic transport, and hepatotoxicity remains the primary reason drugs in 
development fail and approved drugs are withdrawn from the market. For this reason, we propose 
to analyze, across liver compartments, the transport kinetics of fluorescein—a fluorescent marker 
used as a proxy for drug molecules—using intravital microscopy data. To resolve the transport 
kinetics quantitatively from fluorescence data, we account for the effect that different liver 
compartments (with different chemical properties) have on fluorescein’s emission rate. To do so, 
we develop ordinary differential equation transport models from the data where the kinetics is 
related to the observable fluorescence levels by “measurement parameters” that vary across 
different liver compartments. On account of the steep non-linearities in the kinetics and 
stochasticity inherent to the model, we infer kinetic and measurement parameters by generalizing 
the method of parameter cascades. For this application, the method of parameter cascades ensures 
fast and precise parameter estimates from noisy time traces.
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Graphical Abstract
INTRODUCTION
Physiological Context of Hepatotoxicity.
Liver transport is a fundamental physiological process whose significance to human health 
has increased with the proliferation of pharmaceuticals and environmental toxins.1–3 Since 
the liver is a primary venue for the clearance of xenobiotics, it is particularly susceptible to 
drug-induced injury in a process known as hepatotoxicity.4–6 Drug hepatotoxicity is 
associated with inhibition of hepatic transport7–9 through the inhibition of transporters.10,11 
Drug effects on hepatic transporters are also a major cause of drug-drug interactions, 
compromising drug safety and complicating drug dosing.12 Although hepatic side effects are 
a primary focus of preclinical drug evaluations, drug-induced liver injury affects an 
estimated several millions of people each year globally and is the most common cause for 
withdrawal of drugs from the market.13,14
Typically, the effects of a drug on hepatic transport are first evaluated outside animal models 
such as in studies of vesicle preparations or cultured cells.15 While these simplified systems 
yield accurate kinetic transport parameters, they also have key limitations: (1) they do not 
recapitulate the complexity of typical clinical situations, which may include one or more 
pathological conditions in an individual taking a combination of drugs;16 and (2) they lack 
the pharmacokinetic processes that determine drug distributions, confounding prediction of 
in vivo drug effects from in vitro dose-response curves.17,18 In other words, they lack the 
full complexity of in vivo transport, a non-vectorial process mediated by the simultaneous 
activity of multiple transporters.19,20
By contrast, laboratory animals, combined with the tools of intravital microscopy (IVM) 
data,21 provide the necessary physiological context.22 The failure to predict drug transport 
inside the liver from IVM data, however, highlights fundamental shortcomings in how we 
exploit the data. In principle, the data contains information on the mechanism of vectorial 
drug transport involving different transporters, often with overlapping specificities. Imaging 
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methods also, simultaneously, are poised to provide spatial and temporal resolution on how 
drugs might impact liver transport from their point of uptake into hepatocytes through 
secretion into the bile, with secretion back into the blood, or flow in the biliary tract.23,24
Recently, some studies have used IVM21,25,26 to monitor transport kinetics of sodium 
fluorescein27,28 and identify the effects of chronic kidney disease on organic anion transport.
29
 While rich in structure, the IVM data also presents important challenges toward achieving 
a complete picture of fluorescein’s transport kinetics as it evolves from the liver capillaries 
(sinusoids) into the cytosol of the hepatocytes (uptake) and then into the bile canaliculi 
(canalicular secretion), from which they are cleared into the bile. However, fluorescein’s 
emission is deeply dependent on its local chemical environment. That is, the fluorescence 
signal from these probes is sensitive to environmental quenching,30,31 and fluorescein itself 
may exist in multiple forms, for example, the glucuronidated form,30 across liver 
compartments.
Thus, in this study, we combine experiments and theory to develop a quantitative method to 
analyze hepatic transport from fluorescence time measurements using IVM data. In 
particular, we model the kinetics of hepatic transport, in other words, the kinetics of 
transport of fluorescent species, using a set of ordinary differential equations (ODEs).32–37 
We treat the units of fluorescing species in a particular compartment and their kinetics 
between liver compartments as hidden (latent) variables and introduce measurement 
parameters to describe the relationship between the absolute concentrations and fluorescence 
intensity in different observed regions. We calibrate our ODE model, that is, infer kinetic 
and measurement parameters, from noisy fluorescence time traces obtained from IVM using 
the method of parameter cascades.38
Mathematical Methods of ODE Parameter Estimation.
A number of parameter estimation methods exist,39–50 some of which we have recently 
reviewed.51,52 Here, we adapt the method of parameter cascades,38 which is 
computationally efficient, maintains good numerical efficiency for estimation of ODE 
parameters from data,53 works for linear or nonlinear dynamics, straightforwardly estimates 
measurement parameters, and takes simultaneous advantage of all points in a time trace to 
perform parameter inference.54 Using this method, ODE solutions are approximated using 
spline coefficients. These coefficients are estimated with penalized smoothing splines with a 
roughness penalty term.
MATERIALS AND METHODS
Experimental Methods.
Here, we used quantitative IVM data for transport in the liver of rats with 5/6th nephrectomy 
(5/6N)55,56 where hepatic drug transport is impacted by chronic kidney disease.29,56 This 
data was previously published, and information on 5/6N rat models and IVM data collection 
is given in refs 29 and 21.
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ODE Model and Parameter Estimation.
We begin with a set of ODEs describing the evolution in time, t, of a species vector, x, of 
length m whose elements are units of fluorescence in a particular compartment
x. (t) = f(x, t |θ) (1)
In particular, the species coincide with different chemical forms of fluorescein, that is, 
modified by being glucuronidated,30 and unmodified forms in each compartment. The vector 
θ contains parameters (kinetic rates describing transport parameters between liver 
compartments) whose values are a priori unknown. The vector, x, itself is not directly 
observed. Rather, we supplement the dynamical above with the following measurement 
model
y(t) = Hx(t) + є(t) (2)
where y(t) is a noisy vector of length r describing total units of fluorescence measurements 
in each compartment at time t and ϵ describes the noise associated with the measurement 
assuming white noise with zero mean and finite variance (σ2). H is an m × n measurement 
matrix in the measurement equation (eq 2), which relates the state to the measurement 
output similar to an equivalent matrix appearing in Kalman filtering.57 Each element of H is 
called a measurement parameter. For example, a measurement parameter of 0.15 indicates 
that only 15% of the substrate is observed, while the remaining 0.85 is unobserved. It 
naturally follows that all measurement parameters take values between [0, 1]. We define a 
vector of all measurement and kinetic parameters, called structural parameters (θ′ = {θ, 
H}), and assume that the variances associated with the noise are, a priori, known.
Next, we use the method of parameter cascades38 to learn the parameters from the data. To 
do so, we first approximate the solution, x(t), of the ODE (eq 1) with a linear combination of 
K basis functions, Φ = φk , k = 1,…,K, as follows
xi = ∑
k = 1
K
cikφk x = cΦ (3)
where x is the approximation of the curve x in terms of our linear expansion. We use i to 
iterate over the m species in our model and call the expansion coefficients cik nuisance 
parameters. The basis functions must themselves approximate the ODE solutions. We 
selected B-splines as these basis functions allow us to appropriately control solution 
smoothness across time as warranted by the data, which serves as input.41,53 The number of 
basis functions must be large enough to adequately represent x,58 and the function xi must 
be learned by optimizing a global objective function that, at once, satisfies the ODE and 
adequately fits the noisy data.59 We then iterate between two optimization routines until a 
pre-specified criterion for the global optimum is met. In the first optimization step, the 
nuisance parameters, c, are estimated using a smoothing ODE-penalized criterion in a 
process known as inner optimization. Within the inner optimization, the structural 
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parameters are kept fixed, and the nuisance parameters are fitted to data by minimizing the 
following penalized sum of squares.
Jin c |θ′, λ, y = ∑
i = 1
n
|yi − xi|
2 + λPEN(x) (4)
In the inner optimization, the regularization parameter, λ, controls the tradeoff between 
fitting the data and fidelity to the ODEs for each xi. Intuitively, for larger noise, as defined 
by eq 2, we need larger λ as the data themselves become less reliable.
In the outer optimization step, the structural parameters, θ′, are updated by minimizing the 
following sum of squared errors between the data yi and our estimates xi
Jout θ′ | λ, y = ∑
i = 1
n
|yi − xi|
2 (5)
Here, Jout(θ′ | λ, y) is minimized with respect to θ′ by using the Newton–Raphson method. 
The following pseudo-code (further detailed in Supplementary Information, Appendix A) 
sketches this procedure.
Algorithm 1
procedure
Set a value for λ
Pick initial values for c, θ′
Inner optimization loop:
 Estimate c by minimizing Jin c′ |θ′, λ
 given by Eq. (4)
Outer optimization loop:
 Estimate θ′ by minimizing Jout θ′ |y, λ
 given by Eq. (5)
 if θ′ are changed (to within some preset precision), Jin c′ |θ′, λ  is reoptimized with respect to c then goto Inner 
optimization.
 else θ′ = θ′ .
 close;
To be clear, we explicitly include measurement parameters among the structural parameters. 
The ability to incorporate measurement parameters constitutes an important generalization 
of the method of cascades to deal with noisy data that was previously suggested.38 We 
highlight here that the method of cascades is an important, fast, and general alternative to 
extended Kalman filters or other Kalman filter variants.60–62 Kalman filters may solve 
similar problems to that above but may suffer in the case of pronounced non-linearities in 
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the dynamics, that is, eq 1. This is especially relevant to us here as we would like our 
method to hold for a broad range of non-linear dynamics.63,64
In Supplementary Information, Appendix B, we describe in greater detail how confidence 
intervals of parameter estimates are determined. Briefly, here, we mention that if the data are 
poor or data sets are too small for the number of parameters to be estimated, the global 
objective function maybe flat around its maximum and unable to sharply discriminate 
between different parameter values (a problem known as “weak identifiability”65,66). By 
contrast, “structural unidentifiability” arises when model parameters are not independent and 
different parameter choices result in equally good fits.67
In our case, by using a method drawn from ref 68, we identified which structural 
parameter(s) is unidentifiable and input their values from other sources before estimating 
other parameters. To do this, we used an approach proposed in ref 69 detailed in 
Supplementary Information, Appendix B.
Method Validation.
To test our method, we validate its performance on systems of increasing complexity using 
sets of simulated (i.e., synthetic) data where the ground truth is known.
Two-State System.—In the simplest example, we have started with a two-state 
(compartments or pixels) model whose (Markov) kinetics is determined by two transition 
rates. Figure 1 illustrates this simple two-state Markov model.
The linear ODEs describing this system are
dX1
dt = − k+X1 + k−X2
dX2
dt = k+X1 − k−X2
(6)
With measurements
yX1
yX2
= α 00 β
X1
X2
+
є1
є2
(7)
where θ′ = [k+, k−, α, β] is the unknown structural parameter vector. The mean of both ϵ1 
and ϵ2 is zero, and the variance of both is assumed to be known; that is, the measurement 
noise assumed to be Gaussian is fixed in a pre-calibration step. To resolve structural 
unidentifiability (see Supplementary Information, Appendix B), we must specify either α or 
β. For concreteness, we presume that from other experiments, it is known that α = 0.5 and 
thus we are left with three unknown parameters.
The solutions to eqs 6 and 7 are plotted in Figure 2 for parameter values [0.5, 2, 0.5, 0.3] and 
known initial conditions yX1
(0), yX2
(0) = [0, 1] .
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We also tested the accuracy of our approach by adding white noise with different variances, 
namely 0.05, 0.1, and 0.2, to our simulated data. In Figure 2 and Table 1, we show the 
results of our fitting and parameter estimation.
Generalized Two-State System.—We continue testing our approach by generalizing the 
previous example. That is, we have two decoupled sets of ODEs for the dynamics whose 
outputs are coupled by measurement. That is, we have
dX1
dt = − k+X1 + k−X2
dX2
dt = k+X1 − k−X2
(8)
dX1′
dt = − k+′ X1′ + k−′ X2′
dX2′
dt = k+′ X1′ − k−′ X′
(9)
and
yX1
yX2
= α 0 α′ 00 β 0 β′
X1
X2
X1′
X2′
+
є1
є2
(10)
The above reflects, for example, two different fluorescent species (the primed and unprimed) 
hopping between two compartments (subscripted one and two). Measurements on both 
compartments reveal the total amount of fluorescent material in each compartment but do 
not discriminate between the primed and unprimed.
The structural parameter vector here is θ′ = k+, k−, k+′ , k−′ , α, β, α′, β′ . To eliminate structural 
unidentifiability, using the procedure highlighted earlier, we specify α = 0.5 and α′ = 0.25. 
The solutions to eqs 8–10 are plotted in Figure 3 for parameter values [0.3, 0.5, 2.0, 4.0, 0.5, 
0.5, 0.25, 0.15] and initial conditions [yX1 (0), yX2 (0)] = [0,1]. The noise, ϵ1 and ϵ2, is 
treated as we did earlier.
We test the accuracy of our approach by considering white noise with different variances 
(0.05, 0.1, and 0.2) added to our simulated data. In Figure 3 and Table 2, we show the results 
of our fitting and parameter estimation with and without noise.
FitzHugh–Nagumo Model.—Finally, we tested our method with one of the best known 
models, developed by FitzHugh70 and Nagumo et al. to examine the behavior of spike 
potentials in the giant axon of squid neurons. While this model is dissimilar in structure to 
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our hepatic transport model, the FitzHugh–Nagumo model, shown below, is often used as a 
benchmark in ODE parameter estimation problems38,72
dV
dt = c V −
V3
3 + R
dR
dt =
1
c (V − a + bR)
(11)
This system describes the mutual dependency between voltage across an axon membrane, V, 
and a recovery variable R summarizing outward currents. In this case, we set up simulated 
data for parameter values [a, b, c] = [0.2, 0.2, 3] and initial conditions [V(0), R(0)] = 
[ − 1,1].
In addition to the above, we supplement the dynamical model with a measurement model
yV
yR
= α 00 β
V
R
+
є1
є2
(12)
Thus, the parameters to be determined are now θ′ = [a, b, c, α, β]. Identifiability demands 
that we specify either α or β. For this reason, here, we set α = 0.5. For synthetic data 
generated using [0.2, 0.2, 3.0, 0.5, 0.75] and initial conditions [V(0), R(0)] = [ − 1, 1], the 
results are shown in Figure 4 and Table 3.
As expected across all models, increasing the noise variance level decreases our parameter 
estimation accuracy and robustness (i.e., error bar). The amount by which increased noise 
reduces the accuracy and robustness of our estimates depends on the model under 
consideration. So much is clear by comparing, with a variance of 0.2 for the white noise, the 
results from Figure 1 to those of Figure 4.
RESULTS
Full Hepatic Transport Model.
We now construct a model of hepatic transport. Transport in the liver consists of fluorescein 
transport between and through sinusoid blood vessels into the hepatocytes and then into the 
canaliculi.21 The data we have collected consists of fluorescence intensity from fluorescein 
in all three compartments.
To construct our model, we (1) assume no direct transport between sinusoid and canaliculus 
and (2) assume only three compartments (sinusoid, hepatocyte, and canaliculus). In this 
case, we designate fluorescein species in the sinusoid, hepatocyte, and canaliculus as S(t), 
H(t), and C(t), respectively. In full generality, we also consider back flow from the 
hepatocyte back into the sinusoid.
We treat fluorescein in each compartment as a different species with a different 
measurement parameter since each compartment presents variable quencher species and 
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concentrations (e.g., binding proteins reducing fluorescein net emission).21 What is more, 
we consider two forms of fluorescein, both unmodified and glucuronidated as it is known 
that the majority of fluorescein is glucuronidated within 30 min of intravenous injection.30
A schematic of the model is provided in Figure 5. In our model, the species vector, 
previously written as x in eq 1, includes the unit of measurement for unmodified and 
modified (glucuronidated) fluorescein in each compartment. The quantities are given by S, 
H, and C for fluorescein and S, H′, and C′ for glucuronidated fluorescein in each 
compartment. Finally, while we have six species, glucuronidated and unmodified fluorescein 
in three compartments, we only have three measurements, namely the fluorescence intensity 
in each compartment.
Based on the model schematic provided in Figure 5, after prespecifying the input rate into 
the sinusoid thereby setting initial conditions, the dynamical model is given by
dS
dt = − kS HS + kH SH
dH
dt = kS HS − kH S + kH C H − kHTH
dC
dt = kH CH − kCC
(13)
and
dS′
dt = − kS H′ S′ + kH S′ H′
dH′
dt = kS H′ S′ − kH S′ + kH C H′ + kHTH
dC′
dt = kH C′ H′ − kC′ C′
(14)
The measurement model is now
yS
yH
yC
=
α 0 0 α′ 0 0
0 β 0 0 β′ 0
0 0 γ 0 0 γ′
S
H
C
S′
H′
C′
+
є1
є2
є3
. (15)
The parameters α, β, and γ and their primes are our measurement parameters for 
unmodified and glucuronidated fluorescein in each compartment. We note that in this case, 
the measurement matrix H is no longer square or diagonal; at any given time, we have fewer 
measurements than number of species in our model.
Furthermore, just as we did with simulated data, we used the identifiability problem 
procedure (detailed in Supplementary Information, Appendix B) and, on this basis, pre-
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specified the values for the measurement parameters of both fluorescein and glucuronidated 
fluorescein in the sinusoid, α = 0.5 and α′ = 0.25, and also the conversion rate between 
them in the hepatocyte, kHT = 0.5 min−1.
Study on Sham Control and 5/6N Rat Model of Chronic Kidney Disease.
Here, we used IVM data from 5/ 6N rat models as these are often used as models for the 
study of chronic kidney disease.73 To evaluate the functional outcomes of the 5/6N model on 
hepatic transport, we collected IVM data29 in the liver of sham control-operated rats Figure 
6A. In this case, sham control-operated rats were treated with the same anesthetic and 
surgical procedures without kidney removal (as opposed to 5/6N with kidneys removed).
The results for these studies are shown in Tables 4 and 5. Similar to previously published 
work,29 our results also show a meaningful change in hepatic transport in 5/6N as compared 
to the sham control. Concretely, our analysis reveals that the 5/6N rats, when compared to 
the sham control-operated rats, exhibited a decrease rate of hepatic uptake of fluorescein. 
Put differently, we anticipate differences in kS H, kH S, kS′ H, and kH′ S between these 
two cases as hepatic transport is impaired in the 5/6N rat.
To resolve model unidentifiability, we pre-specify kHT as well as the measurement 
parameters α and α′ in our model. We chose kHT and those two parameters as their values 
are the easiest to determine via physiological experiments74–76 or via fluorescence lifetime 
imaging.77 Our quantitative conclusions are insensitive to exact parameter estimates used 
initially for kHT, α, and α′.
Effect of Taurolithocholate.
In the previous subsection, we devised a control to assess the functional consequences of the 
5/6N model and recovered a change in transport rates from the sinusoid to the hepatocyte. 
Now, we look at different treatment controls using taurolithocholate (TLC)-treated rats.29 
TLC is a pharmaceutical agent that inhibits transport from the hepatocyte to the canaliculus 
and out from the canaliculus, so we expect these relevant rates to decrease.
TLC-induced cholestasis is a common experimental model for drug-induced cholestasis.
78–80
 According to previous work, TLC impairs hepatic transport81 and also significantly 
blocks hepatocyte uptake of sodium fluorescein.80 Thus, by using TLC-treated rat models, 
we could evaluate our method to see how well it works in estimating transport rates from the 
hepatocyte to the canaliculus and transport rates from canaliculus out.
The result of blocking hepatocyte uptake of sodium fluorescein using TLC-treated rats on 
the hepatocyte is shown in Figure 6C. The estimated ODE parameter values for this data set 
appear in Table 6 where we note that the blocking effect TLC has on secretions to and from 
the canaliculus recovered by our model as measured by the small values for the rates kH → C 
and kC.
kHT, α, and β′ were pre-specified for the same reasons as for the sham control and 5/6N Rat 
cases above.
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DISCUSSION AND CONCLUSIONS
Drug development is a long and costly endeavor; the average drug costs nearly a billion 
dollars and takes roughly 15 years to bring to market.82,83 Given these costs and timescales, 
it is critical to identify the efficacy and risks associated with a candidate drug early in the 
development process. Clearly improving the prediction of drug failures could substantially 
reduce development costs.83,84 The need for improved tools for preclinical evaluation of 
drugs is the central focus of the FDA’s Critical Path Initiative.85 Although new drugs are 
scrutinized for effects on liver function, adverse effects on the liver comprise the most 
common biological reason for drug failure in the development of new pharmaceuticals86,87 
and the most common cause for withdrawal of drugs from the market.12 The failure to 
predict these problems reflects fundamental shortcomings in the methods that are used in 
preclinical drug studies.
Our long-term goal is to combine mathematical modeling with IVM experimental data to 
determine the effects of drugs on hepatic transport. The theoretical framework we develop 
here provides more accurate and reproducible measures of transport, including pathways that 
cannot be observed by other methods, supporting more powerful studies of in vivo liver 
function. By specifically addressing problems tied to fluorescence measurement, our 
approach could increase the physiological relevance of in vivo studies in ways that could 
impact preclinical evaluations of the hepatic drug effects thereby extending the predictive 
power of in vitro drug development studies, minimizing the numbers of animals needed for 
in vivo studies, and reducing the number of drug failures. As a first step toward developing 
new methods for the estimation of in vivo transport rate parameters, we have presented an 
implementation of the known method of parameter cascades for ODE parameter estimation, 
one that we tailored to IVM experimental data on hepatic transport.
In the context of biophysics, parameter inference methods have a comparatively long history.
88–96
 The goal of parameter estimation is to find unknown parameters of the model that give 
the best fit to a set of experimental data.97 While a number of methods tailored to learning 
parameters from ODEs exist, many of them require that the ODEs be numerically solved,
39,40
 which entails expensive computation and requires knowing the initial values of the 
ODE variables. However, efficient computational methods exist that do not require actually 
solving the ODEs numerically.41–43 A drawback for many of these methods is that they do 
not take into account error approximation when making parameter inferences, which causes 
the well-known bias problem.44 On the other hand, we deal with these problems through 
parameter cascades by defining two nested levels of optimization in our adaptation. In the 
inner optimization loop, we estimated nuisance parameters (coefficients of basis function). 
Then, structural parameters are estimated in the outer optimization loop.
Disadvantages of our method include the fact that weight assigned to the penalty term (the 
regularization parameter) can impact overall inference if unreasonable values are selected.98 
This is also true for any Bayesian inference problem if unusual hyperparameters are 
selected.57 Furthermore, we only determine point estimates rather than full posterior 
distributions over the unknown parameter values.99–106
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Regarding other approaches that focus on parameter estimation such as maximum likelihood 
and Bayesian mehods,107,108 naive implementations demand that ODEs be solved first.
101,104,109
 Here, with parameter cascades, this step is unnecessary even for highly non-linear 
dynamics (as exemplified by the FitzHugh–Nagamo results). On account of its ability to deal 
with non-linear dynamics as well as measurement parameters, our method should be general 
enough to deal with non-linearities introduced, say, by having kinetics dictated by 
Michaelis–Menten ODE forms for all reactions. The latter would be especially relevant to 
capturing transporter saturation if such information is discernible from the data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Schematic of two-state Markov model. Here, we have two rates, k+ and k−, corresponding to 
these two states.
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Figure 2. 
Fits for the synthetic model shown in Figure 1. For each compartment, the results are shown 
after adding white noise with variances of (A) 0.05, (B) 0.1, and (C) 0.2. The dots are 
generated data points, the dashed lines are theoretical curves, and the solid lines are the fits 
on our data. AU here stands for arbitrary units.
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Figure 3. 
Fits for generalized two-state systems. For each compartment, the results of adding white 
noise with variances of (A) 0.05, (B) 0.1, and (C) 0.2 have been shown. The dots are 
generated data points, dashed lines are theoretical curves, and the solid lines are the fits on 
our data.
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Figure 4. 
Fit to the FitzHugh-Nagumo model supplemented by a measurement model. As before, we 
consider the following different noise variance levels: (A) 0.05, (B) 0.1, and (C) 0.2. Details 
in text.
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Figure 5. 
Schematic of hepatic transport model used. We consider five transport rates for fluorescein: 
kS → H for the transport from the sinusoid to the hepatocyte, kH → S from the hepatocyte 
back to the sinusoid, kH → C from the hepatocyte to the canaliculus, and a loss rate kC from 
the canaliculus. We also assume glucuronidated fluorescein is transported via the same 
mechanisms, albeit with rates that have different values, designated by the primed symbols 
above. Finally, kHT represents the transformation of fluorescein into its glucuronidated form 
within the hepatocyte. The arrows show the direction of flow.
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Figure 6. 
Results of studies of fluorescein transport in rat model sham control, 5/6N, and 
taurolithocholate (TLC)-treated Livers. (A) We have sample images from a set of collected 
images from the liver of a rat as the sham control (without removing the kidneys) during 
intravenous injection of sodium fluorescein. On the right-hand side, we see our method’s fit 
to the data with kinetic parameters responsible for the fit reported in Table 4. (B) We show 
results for a 5/6N rat model in which the kidneys were removed. The main difference 
between (A) and (B) is the change in the rate of hepatic uptake of fluorescein as quantified 
by the rates from the sinusoid to the hepatocyte between the sham control and 5/6N rats for 
both glucuronidated and unglucuronidated forms of fluorescein. More details on the rat 
model are provided in ref 29. (C)We show example images collected from a rat treated by 
the agent TLC obtained after intravenous injection. The TLC highly reduces the rate of 
fluorescein uptake into the canaliculus.
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Table 1.
Two-State Resultsa
parameter k+ k− β
Without noise
true values 0.5 2.0 0.3
estimated values 0.5000 2.0000 0.3000
standard deviation 0.0001 0.0002 0.0001
σ2 = 0.05 for the noise
true values 0.5 2.0 0.3
estimated values 0.4555 1.9854 0.3120
standard deviation 0.0466 0.2809 0.0206
σ2 = 0.1 for the noise
true values 0.5 2.0 0.3
estimated values 0.5202 2.2808 0.3185
standard deviation 0.0180 0.1434 0.0650
σ2 = 0.2 for the noise
true values 0.5 2.0 0.3
estimated values 0.5582 1.7767 0.3381
standard deviation 0.1134 0.3351 0.1266
a
Results of parameter estimation for the two-state system captured in Figure 1 with and without considering noise (the rates are in units of min−1). 
The standard deviations reported for the structural parameters are taken from one representative run after determining these parameters over 
multiple runs of a given synthetic data set.
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Table 3.
FitzHugh–Nagumo Model Resultsa
parameter a b c β
Without noise
true values 0.2 0.2 3 0.75
estimated values 0.2001 0.1999 3.0001 0.7500
standard deviation 0.0001 0.0013 0.0032 0.0001
σ2 = 0.05 for the noise
true values 0.2 0.2 3 0.75
estimated values 0.2005 0.1995 3.0020 0.7498
standard deviation 0.0012 0.0016 0.0160 0.0018
σ2 = 0.1 for the noise
true values 0.2 0.2 3 0.75
estimated values 0.1895 0.1841 3.046 0.7702
standard deviation 0.0114 0.0280 0.0243 0.0124
σ2 = 0.2 for the noise
true values 0.2 0.2 3 0.75
estimated values 0.1543 0.2317 2.9056 0.6924
standard deviation 0.0189 0.0372 0.0662 0.0726
a
Results of parameter estimation for the FitzHugh–Nagumo model obtained by considering increasing noise as before (the rates are in units of min
−1). See Table 1 for details on the standard deviation.
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